Characterizing low fluence thresholds for in vitro photodynamic therapy

Biomedical Optics Express

Volumn 6, Issue 3, 2015, Pages 770-779

  Hartl, Brad A ^a   Hirschberg, Henry ^b   Marcu, Laura ^a   Cherry, Simon R ^a  

^a University of California Davis   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; PHOTOSENSITIZERS;

AMINOLEVULINIC ACID; FLUENCE THRESHOLDS; FLUENCES; IN-VITRO; LIGHT DELIVERY; PHOTODYNAMIC THERAPY (PDT); SECOND-GENERATION PHOTOSENSITIZER; SUPERFICIAL DISEASE;

PHOTODYNAMIC THERAPY;

AMINOLEVULINIC ACID;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DOSE RESPONSE; HUMAN; HUMAN CELL; ILLUMINATION; LIGHT RELATED PHENOMENA; LOW FLUENCE THRESHOLD; NON INVASIVE PROCEDURE; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; RADIATION RESPONSE; RADIOLOGICAL PARAMETERS;

EID: 84942363534     PISSN: None     EISSN: 21567085     Source Type: Journal    
DOI: 10.1364/BOE.6.000770     Document Type: Article

References (25)

1. P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B. C. Wilson, and J. Golab, “Photodynamic therapy of cancer: an update,” CA Cancer J. Clin. 61(4), 250–281 (2011).
2. P. Babilas, S. Schreml, M. Landthaler, and R. M. Szeimies, “Photodynamic therapy in dermatology: state-of-theart,” Photodermatol. Photoimmunol. Photomed. 26(3), 118–132 (2010).
3. S. Michels and U. Schmidt-Erfurth, “Photodynamic therapy with verteporfin: a new treatment in ophthalmology,” Semin. Ophthalmol. 16(4), 201–206 (2001).
4. J. N. Silva, P. Filipe, P. Morlière, J. C. Mazière, J. P. Freitas, M. M. Gomes, and R. Santus, “Photodynamic therapy: Dermatology and ophthalmology as main fields of current applications in clinic,” Biomed. Mater. Eng. 18(4-5), 319–327 (2008).
5. L. Costa, M. A. Faustino, M. G. Neves, A. Cunha, and A. Almeida, “Photodynamic inactivation of mammalian viruses and bacteriophages,” Viruses 4(12), 1034–1074 (2012).
6. P. Calzavara-Pinton, M. T. Rossi, R. Sala, and M. Venturini, “Photodynamic antifungal chemotherapy,” Photochem. Photobiol. 88(3), 512–522 (2012).
7. Z. Huang, H. Xu, A. D. Meyers, A. I. Musani, L. Wang, R. Tagg, A. B. Barqawi, and Y. K. Chen, “Photodynamic therapy for treatment of solid tumors--potential and technical challenges,” Technol. Cancer Res. Treat. 7(4), 309–320 (2008).
8. Y. D. Hu, K. Wang, and T. C. Zhu, “A light blanket for intraoperative photodynamic therapy,” Proc. SPIE 7380, 73801W (2009).
9. M. S. Mathews, E. Angell-Petersen, R. Sanchez, C. H. Sun, V. Vo, H. Hirschberg, and S. J. Madsen, “The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids,” Lasers Surg. Med. 41(8), 578–584 (2009).
10. B. C. Wilson and M. S. Patterson, “The physics, biophysics and technology of photodynamic therapy,” Phys. Med. Biol. 53(9), R61–R109 (2008).
11. B. W. Henderson, T. M. Busch, and J. W. Snyder, “Fluence rate as a modulator of PDT mechanisms,” Lasers Surg. Med. 38(5), 489–493 (2006).
12. S. K. Bisland, L. Lilge, A. Lin, R. Rusnov, and B. C. Wilson, “Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors,” Photochem. Photobiol. 80(1), 22–30 (2004).
13. W. Chen and J. Zhang, “Using Nanoparticles to Enable Simultaneous Radiation and Photodynamic Therapies for Cancer Treatment,” J. Nanosci. Nanotechnol. 6(4), 1159–1166 (2006).
14. X. Zou, M. Yao, L. Ma, M. Hossu, X. Han, P. Juzenas, and W. Chen, “X-ray-induced nanoparticle-based photodynamic therapy of cancer,” Nanomedicine (Lond) 9(15), 2339–2351 (2014).
15. M. Haase and H. Schäfer, “Upconverting Nanoparticles,” Angew. Chem. Int. Ed. Engl. 50(26), 5808–5829 (2011).
16. N. M. Idris, M. K. Gnanasammandhan, J. Zhang, P. C. Ho, R. Mahendran, and Y. Zhang, “In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers,” Nat. Med. 18(10), 1580–1585 (2012).
17. R. Laptev, M. Nisnevitch, G. Siboni, Z. Malik, and M. A. Firer, “Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells,” Br. J. Cancer 95(2), 189–196 (2006).
18. R. Robertson, M. S. Germanos, C. Li, G. S. Mitchell, S. R. Cherry, and M. D. Silva, “Optical imaging of Cerenkov light generation from positron-emitting radiotracers,” Phys. Med. Biol. 54(16), N355–N365 (2009).
19. J. Gonzales, G. Zamora, A. Trinidad, L. Marcu, S. Cherry, and H. Hirschberg, “Ultra low fluence rate photodynamic therapy: Simulation of light emitted by the Cerenkov effect,” in (SPIE Proceedings, 2014), 89280F.
20. T. Hatakeyama, Y. Murayama, S. Komatsu, A. Shiozaki, Y. Kuriu, H. Ikoma, M. Nakanishi, D. Ichikawa, H. Fujiwara, K. Okamoto, T. Ochiai, Y. Kokuba, K. Inoue, M. Nakajima, and E. Otsuji, “Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes in human colon cancer cells,” Oncol. Rep. 29(3), 911–916 (2013).
21. S. Sharma, A. Jajoo, and A. Dube, “5-Aminolevulinic acid-induced protoporphyrin-IX accumulation and associated phototoxicity in macrophages and oral cancer cell lines,” J. Photochem. Photobiol. B 88(2-3), 156–162 (2007).
22. SciDAVis, retrieved December 2014, http://scidavis.sourceforge.net/.
23. B. F. Godley, F. A. Shamsi, F. Q. Liang, S. G. Jarrett, S. Davies, and M. Boulton, “Blue light induces mitochondrial DNA damage and free radical production in epithelial cells,” J. Biol. Chem. 280(22), 21061–21066 (2005).
24. T. Takahashi and T. Ogura, “Resonance Raman spectra of cytochrome c oxidase in whole mitochondria,” Bull. Chem. Soc. Jpn. 75(5), 1001–1004 (2002).
25. J. Zhang, K. L. Wong, W. K. Wong, N. K. Mak, D. W. Kwong, and H. L. Tam, “Two-photon induced luminescence, singlet oxygen generation, cellular uptake and photocytotoxic properties of amphiphilic Ru(II) polypyridyl-porphyrin conjugates as potential bifunctional photodynamic therapeutic agents,” Org. Biomol. Chem. 9(17), 6004–6010 (2011).